You are here

Novartis

FDA Refuses to Approve Novartis' $9.7 Billion Cholesterol Drug for Now

Motley Fool

Sat, 12/19/20 - 11:41 pm

complete response letter

Novartis acquires a small biotech and its trio of brain drugs

BioPharma Dive

Thu, 12/17/20 - 11:57 am

Amgen and Novartis tap TV host to jump-start migraine conversations—and fuel understanding

Fierce Pharma

Wed, 12/16/20 - 10:40 pm

celebrity endorsements

Novartis' heart failure med Entresto wins FDA panel backing for bigger patient group—but just how much bigger?

Fierce Pharma

Wed, 12/16/20 - 11:35 am

heart failure with preserved ejection fraction

Roche's MS blockbuster Ocrevus, facing new Novartis competition, scores FDA nod for more-convenient infusion

Fierce Pharma

Tue, 12/15/20 - 08:29 pm

multiple sclerosis

Novartis raises the temp on Eylea rivalry with head-to-head trial win for Beovu in diabetic macular edema

Endpoints

Tue, 12/15/20 - 10:51 am

diabetic macular edema

Novartis/Incyte draw blank with Jakafi in COVID-19

Pharmaforum

Mon, 12/14/20 - 10:35 am

clinical trials

Novartis’ $9.7B PCSK9 drug nabs first OK — now comes the challenge of finding a market

Endpoints

Fri, 12/11/20 - 11:06 am

SABCS: Novartis touts Kisqali's 5-year breast cancer survival, advantage over Pfizer's Ibrance

Fierce Pharma

Wed, 12/9/20 - 10:51 am

ASH20: Out to shake up CML once again, Novartis lays out head-to-head between third-gen Gleevec scion and Pfizer rival

Endpoints

Tue, 12/8/20 - 11:08 pm

Novartis signs ophthalmology AI deal with RetinAI

Pharmaforum

Tue, 12/8/20 - 10:35 am

ASH: Novartis makes its Kymriah case in follicular lymphoma, but another Gilead showdown awaits

Fierce Pharma

Sat, 12/5/20 - 11:38 pm

follicular lymphoma

clinical trials

Novartis’s big wager on RNAi approaches the finish line

EP Vantage

Wed, 11/25/20 - 10:27 am

Novartis taps smartpatient for app to support wet AMD patients

Pharmaforum

Mon, 11/23/20 - 10:14 am

wet age-related macular degeneration

digital therapeutics

Novartis Inks $1.35 Billion Deal with Mesoblast for Remestemcel-L for COVID-19 ARDS

BioSpace

Fri, 11/20/20 - 11:08 am

clinical trials

FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar

Pharmaforum

Thu, 11/19/20 - 10:33 am

Samsung Bioepis

Unmet Need in Dry Eye Disease Market Leaves Room for Other Drugmakers to Step In

BioSpace

Fri, 11/13/20 - 12:49 pm

dry eye disease

Kala Pharmaceuticals

Novartis’ Ilaris fails in late-stage COVID-19 trial

Pharmaforum

Fri, 11/6/20 - 09:59 am

clinical trials

Novartis’ Aimovig tops topiramate in migraine face-off

Pharmaforum

Wed, 11/4/20 - 10:20 am

clinical trials

Novartis adds new restriction to 340B discount policy

Beckers Hospital Review

Mon, 11/2/20 - 11:03 pm

Pages